Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer
Information source: Massachusetts General Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Ovarian Cancer; Peritoneal Carcinoma; Tubal Carcinoma
Intervention: Iressa (ZD1839) (Drug); Arimidex (Anastrozole) (Drug)
Phase: Phase 2
Sponsored by: Massachusetts General Hospital
Official(s) and/or principal investigator(s):
Carolyn Krasner, MD, Principal Investigator, Affiliation: Massachusetts General Hospital
The main purpose of this study is to determine the effects (good and bad) Iressa plus
anastrozole has on patients with relapsed ovarian cancer.
Official title: A Phase II Study of ZD1839 (Iressa) Plus Anastrozole (Arimidex) in Patients With Relapsed Ovarian Cancer
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: To define the median time to termination of treatment with Iressa and anastrozole in patients with asymptomatic relapsed ovarian cancer.
To define the median time to progression of this patient population
to assess the tumor response and safety of this treatment.
- Patients will receive Iressa and anastrozole orally once daily until treatment is
ended. Treatment will end if any of the following occur: Unacceptable adverse effects;
bowel obstruction; initiation of systemic chemotherapy; development of new ascites or
pleural effusions, development of co-morbid disease or disease progression.
- Patients will be given a drug log in which to record the date and time they take their
pills, as well as any symptoms and concomitant medications.
- Patients will be seen monthly for the following tests and procedures; a physical
examination and repeat blood work. Patients who remain free of clinical symptoms
should have repeat abdominal/pelvic CT scans and chest x-rays on an every 3 month
Minimum age: 18 Years.
Maximum age: N/A.
- Histologic or cytologic history diagnosis of primary ovarian, primary peritoneal or
- Asymptomatic from ovarian cancer
- Evidence of recurrent ovarian, peritoneal or tubal carcinoma
- Tumor sample must be positive for ER and/or PR
- 18 years of age or older
- ECOG performance status of less than or equal to 1
- Must be able to tolerate oral intake
- Known hypersensitivity to Iressa or any of the excipients of this product
- Other coexisting malignancies or malignancies diagnosed within the last 5 years
- Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital
or St. John's wort
- Treatment with a non-approved or investigational drug within 30 days
- Any unresolved chronic toxicity greater than CTC grad 2 from previous anticancer
therapy (except alopecia)
- Incomplete healing from previous oncologic or other major surgery
- Serum creatinine level greater than CTC grade 2
- Pregnant or breast feeding
- Severe uncontrolled systemic disease
- Significant clinical disorder or laboratory finding that makes it potentially unsafe
for the subject to participate
- Patients currently receiving other investigational antineoplastic agents, on systemic
chemotherapy or under radiation therapy treatment
- Patients previously treated with anastrozole or other aromatase inhibitor
- Unable to tolerate oral medications
- Clinical and/or radiographic evidence of current or impending bowel obstruction
Locations and Contacts
Dana-Farber Cancer Institute, Boston, Massachusetts 02115, United States
Massachusetts General Hospital, Boston, Massachusetts 02114, United States
Starting date: October 2003
Last updated: December 4, 2012